Results 151 to 160 of about 5,288 (183)

Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification. [PDF]

Oncotarget
Patel JN, Singh J, Ghosh N.
europepmc   +1 more source

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor. [PDF]

Int J Mol Sci, 2020
Lee KW, Lee WH, Han BS, Lee JH, Doo EK, Kim JH.   +5 more
europepmc   +1 more source

The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia. [PDF]

Front Oncol
Yang S, Wei R, Shi H, Wang Y, Lai Y, Zhao X, Lu J, Schmitz N.   +7 more
europepmc   +1 more source

A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B‑Cell Signaling

ACS Omega, 2017
Einav Ratzon, Itai Bloch, Meshel Nicola, Elad Cohen, Nili Ruimi, Nesly Dotan, Meytal Landau, Maayan Gal   +7 more
doaj   +1 more source

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. [PDF]

J Manag Care Spec Pharm
Huntington SF, Manzoor BS, Jawaid D, Puckett JT, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi JA.   +7 more
europepmc   +1 more source

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model. [PDF]

Heliyon, 2019
Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R.   +5 more
europepmc   +1 more source

The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity. [PDF]

Br J Haematol, 2020
Godwin CD, Bates OM, Garling EE, Beddoe ME, Laszlo GS, Walter RB.   +5 more
europepmc   +1 more source

A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation. [PDF]

R Soc Open Sci, 2019
Abdelhameed AS, Attwa MW, Al-Shaklia NS, Kadi AA.   +3 more
europepmc   +1 more source

Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. [PDF]

Signal Transduct Target Ther, 2020
Liu J, Liang Q, Wang A, Zou F, Qi Z, Yu K, Liu Q, Chen C, Liu J, Liu Q.   +9 more
europepmc   +1 more source

Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. [PDF]

Mult Scler
Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS.   +13 more
europepmc   +1 more source